The orchestration of T cell activation is central to immune defence and self-tolerance. Recent advances have revealed that T cells integrate signals from their antigen receptors alongside a network of ...

Low-dose aspirin may limit cancer metastasis by inhibiting platelet activation and enhancing T-cell immunity, supporting biomarker guided use while balancing bleeding risk overall.

The activation and regulation of T cells are fundamental to immune homeostasis and effective defence mechanisms. Ubiquitin ligases, such as c-Cbl and Cbl-b, serve as pivotal regulators by targeting ...

How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy ...

The FDA has granted fast track designation (FTD) to LBL-034, an investigational GPRC5D/CD3 bispecific T-cell engager (BiTE), for patients with relapsed/refractory multiple myeloma (R/R MM).

Immunotherapy has revolutionized the way physicians treat patients. Previously, chemotherapy was the standard-of-care with the goal to eliminate tumor cells by dysregulating their ability to ...

Treatment with nivolumab (Opdivo) had limited benefit in patients with multiple myeloma (MM) or non-Hodkin lymphoma (NHL) ...

A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has developed a novel cancer immunotherapy strategy that forces tumors to expose ...

Viruses are effective tools for delivering genetic material into cells, and scientists have taken advantage of viral transduction in numerous ways, such as constructing chimeric antigen receptor (CAR) ...

Contrary to public concerns, receiving frequent COVID-19 booster vaccinations will not weaken the immune system, providing reassurance to vulnerable groups facing new variants. Study: No evidence of ...

The Notch signaling pathway plays a pivotal role in determining cell fate, especially in the development and function of T cells. But mimicking this highly mechanical, contact-dependent pathway in the ...

Study data show stronger Ph+ acute lymphoblastic leukaemia immune activation with dasatinib plus blinatumomab than with ponatinib combinations, highlighting sustained natural killer cell responses.